Showing 2241-2250 of 2973 results for "".
- ASDS 2018 Survey: Close to 70 percent of Consumers Thinking About Cosmetic Treatmentshttps://modernaesthetics.com/news/asds-2018-survey-close-to-70-percent-of-consumers-are-thinking-about-cosmetic-treatments/2472034/Almost 70 percent of consumers are considering a cosmetic treatment, and more than half would prefer to pay more up front to lower their annual skin care costs, according to the 2018 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmeti
- Allergan Shares Results of Higher Dose Botox Cosmetic for the Treatment Glabellar Lineshttps://modernaesthetics.com/news/allergan-share-results-of-higher-dose-botox-cosmetic-for-the-treatment-glabellar-lines/2472035/Allergan plc clinical study results of higher doses of Botox Cosmetic compared to Botox Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines. Allergan conducted this trial to evaluate the duration of effect and safety of Botox
- Allergan Acquires Bonti for $195Mhttps://modernaesthetics.com/news/allergan-acquires-bonti-for-195m/2472036/Allergan acquired Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the
- Inside Spotlyte: Allergan's Digital Hub to Educate Consumers About Medical Aesthetic Treatmentshttps://modernaesthetics.com/news/inside-spotlyte-allergans-digital-hub-to-educate-consumers-about-medical-aesthetic-treatments/2472038/Allergan has launched Spotlyte, described as an innovative digital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines. Spotlyte
- Candela Acquires Ellipsehttps://modernaesthetics.com/news/candela-acquires-ellipse/2472039/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Thermi Debuts Arvati Platformhttps://modernaesthetics.com/news/themi-debuts-arvati-platform/2472041/Thermi, an Almirall company, is launching Arvati, a next-generation 510K US Food and Drug Administration-cleared, true temperature-controlled radiofrequen
- Cynosure to Distribute Porter Instrument's Nitrous Oxide and Oxygen System in Aesthetics Markethttps://modernaesthetics.com/news/cynosure-to-distribute-porter-instruments-nitrous-oxide-and-oxygen-system-in-aesthetics-market/2472047/Hologic, Inc.'s Cynosure division has penned a deal with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter Instrument&#
- Evolus Resubmits BLA for DWP-450 Ahead of Schedulehttps://modernaesthetics.com/news/evolus-resubmits-bla-for-dwp-450-ahead-of-schedule/2472049/Evolus has resubmitted its Biologics License Application (BLA) for its lead product candidate, DWP-450 (prabotulinumtoxinA), to the FDA. The resubmission follows the receipt of a Complete Response Letter (“CRL”) from the FDA in May 2018 which necessita
- Bonti's Novel Neurotoxin Shows Promise in Early Study of Scar Reduction After Mohs Surgeryhttps://modernaesthetics.com/news/bontis-novel-neurotoxin-shows-promise-in-early-study-of-scar-reduction-after-mohs-surgery/2472052/Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical
- With New Applicator, Cryolipolysis is an Option for Male Pseudogynecomastiahttps://modernaesthetics.com/news/withnew-applicator-cryolipolysis-is-an-option-for-male-pseudogynecomastia/2472059/Thanks to a conformable surface applicator, cryolipolysis can be a safe and effective way to treat male pseudogynecomastia, according to a recent